Peptide Initiative

Peptides · Peptide comparison

Buserelin vs Gonadorelin (GnRH)

A synthetic GnRH agonist that suppresses hormones to help treat prostate cancer, endometriosis, and infertility

The master hormone that controls your reproductive system and fertility

  • Hormone Support
  • Hormone Support

At a glance

Quick comparison

Dose rangeBuserelin200–200 mcgGonadorelin (GnRH)100–100 mcg
FrequencyBuserelinOnce dailyGonadorelin (GnRH)Once daily
AdministrationBuserelinSubcutaneous injectionGonadorelin (GnRH)Subcutaneous injection
Cycle lengthBuserelinOngoing/indefiniteGonadorelin (GnRH)Ongoing/indefinite
Onset speedBuserelinModerate (1-2 weeks)Gonadorelin (GnRH)Moderate (1-2 weeks)
Evidence levelBuserelinStrong human trials (Phase 3 or FDA approved)Gonadorelin (GnRH)Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Hormone Suppression

Buserelin90%
Gonadorelin (GnRH)No recorded rating

Cancer Management

Buserelin86%
Gonadorelin (GnRH)No recorded rating

Fertility Support

Buserelin83%
Gonadorelin (GnRH)No recorded rating

Reproductive Health

BuserelinNo recorded rating
Gonadorelin (GnRH)95%

Hormone Balance

BuserelinNo recorded rating
Gonadorelin (GnRH)90%

Ovulation Support

BuserelinNo recorded rating
Gonadorelin (GnRH)88%

Technical data

Compound specifications

Buserelin

Molecular formula
C60H86N16O13
Molecular weight
1239.4 g/mol
Half-life
2-4 hours (subcutaneous), 30-60 minutes (intranasal); longer for depot formulation (28-40 days)
Bioavailability
~1% (oral); ~10-15% (intranasal); ~95% (subcutaneous)
CAS number
57773-65-6

Gonadorelin (GnRH)

Molecular formula
C55H75N17O13
Molecular weight
1182.3
Half-life
2-4 minutes
Bioavailability
Varies by route: ~5-20% (intranasal), 100% (IV/IM injections)
CAS number
34973-08-5

Protocols

Dosing compared

Buserelin

Subcutaneous

  • 500 mcgEvery 8 hours (3 times daily) · First 7 daysThe product label starts prostate cancer treatment with 500 mcg under the skin every 8 hours for the first week [5].
  • 200 mcgOnce daily · Ongoing maintenanceAfter the first week, the label switches to 200 mcg once daily under the skin for ongoing treatment [5].

Intranasal

  • 400 mcg (2 sprays per nostril)3 times daily (1,200 mcg/day) · Ongoing maintenanceThe nasal spray option delivers 400 mcg three times a day as maintenance, an alternative to daily injections [5].

Implant

  • 6.3 mgOnce every 2 months · Long-termA long-acting implant placed under the skin slowly releases buserelin over about 2 months, so no daily dosing is needed [5].
  • 9.45 mgOnce every 3 months · Long-termA larger implant lasts about 3 months between placements [5].

Gonadorelin (GnRH)

Subcutaneous

  • 100 mcgSingle dose · One-time diagnostic testFDA-labeled gonadotropin (LH/FSH) stimulation test for pituitary reserve; 100 mcg given once subcutaneously (or IV), with LH measured at 0, 15, 30, 45, 60 and 120 minutes (Factrel) [4].

Intravenous

  • 5 mcg per pulse (range 1-20 mcg)Every 90 minutes via pulsatile pump · One or more ovulatory cycles; reassessed at 21-day intervalsFDA-labeled pulsatile regimen for ovulation induction in hypothalamic amenorrhea (Lutrepulse); intravenous pulsatile delivery gave better results than subcutaneous [5]. The 2-4 minute half-life makes pulsatile delivery essential.

Applications

Best suited for

Buserelin

Managing advanced prostate cancer
Buserelin is particularly well-suited for individuals focused on managing advanced prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Treating endometriosis and reducing associated pain
Buserelin is particularly well-suited for individuals focused on treating endometriosis and reducing associated pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Optimizing ovarian response during fertility treatments
Buserelin is particularly well-suited for individuals focused on optimizing ovarian response during fertility treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Gonadorelin (GnRH)

Improving fertility and conception chances
Gonadorelin (GnRH) is particularly well-suited for individuals focused on improving fertility and conception chances. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Regulating irregular menstrual cycles
Gonadorelin (GnRH) is particularly well-suited for individuals focused on regulating irregular menstrual cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Enhancing reproductive hormone levels
Gonadorelin (GnRH) is particularly well-suited for individuals focused on enhancing reproductive hormone levels. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting natural pregnancy attempts
Gonadorelin (GnRH) is particularly well-suited for individuals focused on supporting natural pregnancy attempts. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Buserelin

No side effects recorded.

Gonadorelin (GnRH)

Common

  • Mild headache
  • Local injection site reactions (redness, swelling)
  • Temporary hot flashes
  • Mood changes or emotional sensitivity
  • Nausea or mild stomach upset
  • Allergic skin reactions
  • Dizziness or lightheadedness
  • Temporary changes in vision
  • Joint or muscle aches
  • Insomnia or sleep disturbances
  • Severe allergic reactions (difficulty breathing, swelling)
  • Severe hormonal imbalance symptoms
  • Ovarian hyperstimulation syndrome (OHSS)
  • Signs of blood clots (chest pain, leg swelling)
  • Severe mood changes or depression

Serious

  • Severe allergic reaction

Research status

Safety & evidence

Buserelin

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Not FDA approved; no buserelin application in Drugs@FDA. Approved in Canada as SUPREFACT for advanced prostate cancer (injection and nasal solution) and endometriosis (nasal solution).
Safety overview
Buserelin is a GnRH agonist approved in Canada and Europe (not in the US), with safety data from Phase 3 trials and decades of clinical use, but carries well-documented risks from intentional testosterone/estrogen suppression. The initial testosterone flare (first 2-3 weeks) can worsen prostate cancer symptoms and cause tumor flare pain in 10-20% of patients. Long-term use causes bone density loss of 2-3% annually, with vertebral fractures in 10-20% of long-term users. Cardiovascular risks include increased MI and stroke in men over 65. Hot flashes affect 40-80%, erectile dysfunction is nearly universal, and liver enzyme elevations occur in 5%. Nasal spray formulation causes local irritation in 20-30% of users.

Contraindications

  • Pregnancy or breastfeeding
  • Hypersensitivity to GnRH agonists
  • Certain bone diseases when long-term use is planned

Gonadorelin (GnRH)

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Previously FDA approved: FACTREL (1982) as a diagnostic test of pituitary gonadotropin reserve and LUTREPULSE (1989) for ovulation induction. Both human products are discontinued in the US.
Safety overview
Gonadorelin is native GnRH and carries the safety profile established over 40+ years of clinical use in reproductive endocrinology. As the body's natural hormone, it produces minimal local side effects when dosed appropriately. The critical safety concern with gonadorelin is the initial flare effect within 24-48 hours of first dose—temporary elevation in FSH and LH—which can paradoxically suppress sex hormones before the desired stimulation occurs. This flare makes gonadorelin unsuitable for some conditions and explains why synthetic analogs (agonists, antagonists) are preferred in many modern fertility protocols.

Contraindications

  • Pregnancy or breastfeeding
  • Hormone-sensitive cancers (breast, prostate, ovarian)
  • Severe pituitary or hypothalamic disease
  • Undiagnosed abnormal vaginal bleeding
  • Known hypersensitivity to GnRH

Decision guide

Which is right for you?

Buserelin

Choose Buserelin if…

  • Managing advanced prostate cancer
  • Treating endometriosis and reducing associated pain
  • Optimizing ovarian response during fertility treatments

Gonadorelin (GnRH)

Choose Gonadorelin (GnRH) if…

  • Improving fertility and conception chances
  • Regulating irregular menstrual cycles
  • Enhancing reproductive hormone levels
  • Supporting natural pregnancy attempts